









市场行情
/
股票
/
nasdaq-onc
/

百济神州

ONC

337.890USD

+17.520+5.47%

收盘 01/09, 16:00（美东）报价延迟15分钟

34.39B总市值

549.39市盈率 TTM



百济神州

337.890

+17.520+5.47%

概览公司财务分析

概览

公司

财务

分析

关于百济神州公司

BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

百济神州简介



公司代码ONC

公司名称Beigene Ltd

上市日期Mar 02, 2016

CEOOyler (John Victor)

员工数量11000

证券类型Depository Receipt

年结日Mar 02

公司地址c/o BeOne Medicines I GmbH

城市BASEL

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Switzerland

邮编4051

电话41616851900

网址https://beonemedicines.com/

公司代码ONC

上市日期Mar 02, 2016

CEOOyler (John Victor)

百济神州公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Xiaobin Wu, Ph.D.

President, Chief Operating Officer

10.89K

Mr. John Victor Oyler

Co-Founder, Executive Chairman of the Board, Chief Executive Officer

Mr. Michael J. Goller

Non-Executive Independent Director

Mr. Ranjeev Krishana

Lead Non-Executive Independent Director

Mr. Nuoqing (Michael) Yi

Non-Executive Independent Director

Dr. Xiaodong Wang, Ph.D.

Co-Founder, Non-Executive Director

Dr. Eric E. Hedrick, M.D.

Interim Chief Medical Officer, Immuno-Oncology

Mr. Anthony C. (Tony) Hooper

Non-Executive Independent Director

Dr. Corazon Dating (Corsee) Sanders, Ph.D.

Non-Executive Independent Director

Dr. Han (Margaret) Dugan, M.D.

Non-Executive Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Xiaobin Wu, Ph.D.

President, Chief Operating Officer

10.89K

Mr. John Victor Oyler

Co-Founder, Executive Chairman of the Board, Chief Executive Officer

Mr. Michael J. Goller

Non-Executive Independent Director

Mr. Ranjeev Krishana

Lead Non-Executive Independent Director

Mr. Nuoqing (Michael) Yi

Non-Executive Independent Director

Dr. Xiaodong Wang, Ph.D.

Co-Founder, Non-Executive Director

收入明细

单位: USD更新时间: 1月6日周二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Product

1.37B

97.35%

BRUKINSA

1.04B

73.69%

Tislelizumab

190.62M

13.50%

XGEVA

84.24M

5.97%

BLINCYTO

30.48M

2.16%

其他

-1.31B

-92.66%

地区USD

名称

营收

占比

United States

754.86M

53.45%

China

439.88M

31.15%

Europe

166.58M

11.79%

ROW

50.97M

3.61%

业务

地区

业务USD

名称

营收

占比

Product

1.37B

97.35%

BRUKINSA

1.04B

73.69%

Tislelizumab

190.62M

13.50%

XGEVA

84.24M

5.97%

BLINCYTO

30.48M

2.16%

其他

-1.31B

-92.66%

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

Amgen Inc

17.27%

Baker Bros. Advisors LP

8.02%

PRIMECAP Management Company

4.63%

Capital International Investors

4.60%

Fidelity Management & Research Company LLC

3.43%

其他

62.04%

持股股东

占比

Amgen Inc

17.27%

Baker Bros. Advisors LP

8.02%

PRIMECAP Management Company

4.63%

Capital International Investors

4.60%

Fidelity Management & Research Company LLC

3.43%

其他

62.04%

股东类型

持股股东

占比

Investment Advisor

17.53%

Corporation

17.28%

Hedge Fund

8.21%

Investment Advisor/Hedge Fund

3.74%

Sovereign Wealth Fund

0.92%

Research Firm

0.57%

Pension Fund

0.03%

Family Office

0.02%

Family Office

0.02%

其他

51.66%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

564

34.03M

31.03%

-4.53M

2025Q3

565

40.04M

36.51%

-2.11M

2025Q2

558

63.29M

57.54%

+456.15K

2025Q1

585

69.06M

63.84%

+3.36M

2024Q4

575

70.01M

71.38%

+1.65M

2024Q3

603

67.03M

68.90%

-2.04M

2024Q2

601

66.99M

69.35%

-2.19M

2024Q1

621

66.56M

67.86%

-955.35K

2023Q4

626

65.12M

66.49%

-3.71M

2023Q3

632

67.27M

67.88%

-2.05M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Amgen Inc

18.94M

17.27%

Feb 20, 2025

Baker Bros. Advisors LP

8.80M

8.02%

Sep 30, 2025

PRIMECAP Management Company

5.08M

4.63%

-7.82K

-0.15%

Sep 30, 2025

Capital International Investors

5.05M

4.6%

+161.05K

+3.30%

Sep 30, 2025

Fidelity Management & Research Company LLC

3.76M

3.43%

+345.36K

+10.12%

Sep 30, 2025

HHLR Advisors, Ltd.

1.03M

0.94%

Sep 30, 2025

Temasek Holdings Pte. Ltd.

1.01M

0.92%

+999.00

+0.10%

Sep 30, 2025

T. Rowe Price International Ltd

941.86K

0.86%

+9.96K

+1.07%

Sep 30, 2025

T. Rowe Price Associates, Inc.

688.71K

0.63%

+600.48K

+680.59%

Sep 30, 2025

Invus Public Equities Advisors, LLC

492.99K

0.45%

-17.00K

-3.33%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

VanEck Biotech ETF

4.03%

First Trust NYSE Arca Biotechnology Index Fund

3.26%

Tema Oncology ETF

2.65%

Global X Aging Population ETF

2.41%

Virtus LifeSci Biotech Products ETF

1.8%

iShares Biotechnology ETF

1.71%

ProShares Ultra Nasdaq Biotechnology

1.02%

Invesco Nasdaq Biotechnology ETF

1.02%

National Security Emerging Markets Index ETF

0.83%

Capital Group Global Equity ETF

0.79%

VanEck Biotech ETF

占比4.03%

First Trust NYSE Arca Biotechnology Index Fund

占比3.26%

Tema Oncology ETF

占比2.65%

Global X Aging Population ETF

占比2.41%

Virtus LifeSci Biotech Products ETF

占比1.8%

iShares Biotechnology ETF

占比1.71%

ProShares Ultra Nasdaq Biotechnology

占比1.02%

Invesco Nasdaq Biotechnology ETF

占比1.02%

National Security Emerging Markets Index ETF

占比0.83%

Capital Group Global Equity ETF

占比0.79%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

百济神州的前五大股东是谁？



百济神州的前五大股东如下：
Amgen Inc持有股份：18.94M，占总股份比例：17.27%。
Baker Bros. Advisors LP持有股份：8.80M，占总股份比例：8.02%。
PRIMECAP Management Company持有股份：5.08M，占总股份比例：4.63%。
Capital International Investors持有股份：5.05M，占总股份比例：4.60%。
Fidelity Management & Research Company LLC持有股份：3.76M，占总股份比例：3.43%。